Memory profiling with paired associate learning in Alzheimer's disease, mild cognitive impairment, and healthy aging

K E Pike1, C C Rowe2, S A Moss1

  • 1School of Psychology, Psychiatry and Psychological Medicine.

Neuropsychology
|November 13, 2008
PubMed

Insights

Distinguishing Alzheimer's disease (AD) from mild cognitive impairment (MCI) is challenging. A novel paired associate learning (PAL) task showed memory profiling may not reliably differentiate AD progression in MCI patients.

Area of Science:

  • Neuroscience
  • Cognitive Psychology
  • Neurology

Background:

  • Mild cognitive impairment (MCI) increases Alzheimer's disease (AD) risk, but many cases do not progress.
  • Memory profiling aims to predict AD development in MCI.
  • Existing paired associate learning (PAL) tasks lack memory profiling capabilities.

Purpose of the Study:

  • To develop and validate a novel PAL task for memory profiling.
  • To differentiate memory profiles in individuals with AD, MCI, and healthy controls.
  • To assess the clinical utility of memory profiling for AD diagnosis and MCI assessment.

Main Methods:

  • Development of a novel PAL task.
  • Testing the task in participants with AD (n=19), amnestic MCI (n=17), and normal elderly controls (n=33).
  • Analysis of memory profiles (encoding vs. retrieval) across different recognition formats and a validated verbal learning test.

Main Results:

  • The AD group unexpectedly showed a retrieval profile for PAL with yes-no recognition.
  • An encoding profile was observed in the AD group for forced-choice recognition and the California Verbal Learning Test.
  • Significant heterogeneity and intraindividual discordance in memory profiles were found within AD and MCI groups.

Conclusions:

  • Memory profiling using PAL tasks may not be clinically applicable for differentiating AD progression in MCI.
  • The findings challenge the diagnostic utility of memory profiling in AD and MCI assessment.
  • Heterogeneity in memory profiles complicates the use of this method for differential diagnosis.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...